Dana-Farber/Harvard Cancer Center

Running trials

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

  NCT06955169· Phase 2· RTOG Foundation, Inc.· Source

• Recruiting

  XL092 and Cemiplimab in BRAF WT Thyroid Cancer

  NCT06902376· Phase 1· UNC Lineberger Comprehensive Cancer Center· Source

• Recruiting

  A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

  NCT06901531· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Study of MGC028 in Participants With Advanced Solid Tumors

  NCT06723236· Phase 1· MacroGenics· Source

• Recruiting

  A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

  NCT05137054· Phase 1· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

  NCT05060016· Phase 2· Amgen· Source

• Recruiting

  Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

  NCT04031677· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Active, not recruiting

  Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

  NCT04258943· Phase 1/2· Children's Oncology Group· Source

• Active, not recruiting

  Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

  NCT04431479· Fred Hutchinson Cancer Center· Source

• Recruiting

  Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

  NCT03564340· Phase 1/2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

  NCT02455557· Phase 2· Roswell Park Cancer Institute· Source

• Recruiting

  Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

  NCT02582697· Phase 3· University of Sydney· Source

• Active, not recruiting

  Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

  NCT01920932· Phase 2· St. Jude Children's Research Hospital· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma

  NCT00846742· Phase 2· St. Jude Children's Research Hospital· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma2 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Meningioma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Sarcoma1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Completed

  The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation

  NCT03640325· Seattle Children's Hospital· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Kidney cancer22 works · 0 trials
• Metastatic breast cancer14 works · 0 trials